Cancer neoepitopes
AssigneeNantOmics, LLC
InventorsStephen Charles Benz, Andrew Nguyen, Charles Joseph Vaske, John Zachary Sanborn
Life of this patent
Estimating the term…
Abstract
Certain universal neoepitopes and cancer specific neoepitopes and methods therefor are presented that may be used in immunotherapy and cancer diagnosis. Preferred therapeutic and diagnostic compositions include antibodies or fragments thereof that bind to neoepitopes on cancer cells.
Claims25
A method of directing an agent to a cancer cell, comprising:
- contacting the cancer cell with an antibody or fragment thereof that binds to a cancer neoepitope in an AGGF1 (angiogenic factor with g-patch and FHA domains 1) protein, and wherein the cancer neoepitope is formed by a V202L mutation in the AGGF1 protein.
5-6. (canceled)
(canceled)
12-16. (canceled)
An antibody or fragment thereof that binds to a cancer neoepitope in an AGGF1 protein, wherein the cancer neoepitope is formed by a V202L mutation in the AGGF1 protein, and wherein the cancer neoepitope has a sequence of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3.
19-24. (canceled)
A method of directing an agent to a breast cancer cell, comprising:
- contacting the cancer cell with an antibody or fragment thereof that binds to a cancer neoepitope having a sequence of any one of SEQ ID NO:4 to SEQ ID NO:28, of any one of SEQ ID NO:29 to SEQ ID NO:53, of any one of SEQ ID NO:54 to SEQ ID NO:78, or of any one of SEQ ID NO:79 to SEQ ID NO:103.
35-49. (canceled)
Dependencies are inferred from the claim text.